It was reported that the perforator did not disengage.There was impact on the dura matter, and a laceration of the dura matter and opening of orbit which conduct to leakage of csf without blood leakage.The surgery time was increased by 30 minutes however, the surgeon estimates that patient will not have clinical consequences at term.
|
Perforator was received for evaluation.Dhr - there is no indication that the production process may have contributed to this complaint.Device identifier # (b)(4), lot j0896g, manufacture date: not provided, and expiration date: not provided, from the 261221 perforator product family.Failure analysis - visually inspected: anomalies include a worn label, blood, and organic matter.Functional test per procedure: was found to performed as intended.The cause cannot be confirmed, as no issues relevant to the failure were noted from the dhr review, trending, or failure analysis, also proper finished goods testing was performed prior to release.Between 05nov2019 and 30jun2020, approximately 2,200 mdrs submitted electronically by integra lifesciences via trackwise, integra's complaint handling system, were not received by cdrh due to a computer system issue.Within this time period, an error with integra's middleware, which facilitates communications between trackwise and the fda system, caused the complaint records to close and indicate we had received an acknowledgement 3 from the fda when we had not.Integra interpreted the acknowledgement as a successful submission; however, subsequent investigation revealed the acknowledgement 3 received was from our middleware and not from the fda (these acknowledgements have been retained as part of the documentation of the mdr).The malfunction was related to the relocation of the trackwise application to a new data center during the transition of integra's corporate headquarters from plainsboro, nj to princeton, nj.Previously, integra had been successfully receiving acknowledgements 1, 2, and 3 from the fda, and our records reflect these acknowledgements, including the date and time stamps.Capa pr 229048 and nc 20-011 have been opened by integra to further investigate the nonconformance and develop a corrective action plan.The middleware error has been corrected, and integra has filed mdrs since the correction and verified that the appropriate acknowledgements have been received from the fda.Integra is resubmitting all impacted mdr reports for the time period 05nov2019 through 30jun2020.Integra lifesciences contacted (b)(4) office of product evaluation and quality on july 8-9, 2020 to report these issues regarding mdr reports.
|